An analysis of critical late breaking sessions at ACC and ESOC 2022
An analysis of critical late breaking sessions at ACC and ESOC 2022
Airfinity's cardio team outline the most impactful science presented in the field of lipid lowering therapies and novel antithrombotic drugs presented at the last two major cardiovascular conferences, ACC 2022 and ESOC 2022.
Discussion points include:
→ The strengths and limitations of late breaking trial data.
→ The development of novel candidates.
→ Results from the following trials: TRANSLATE-TIMI70, APOLLO, PACIFIC-AF, and ATTICUS
→ Insights into how these may affect treatment landscapes going forward.
Fill out the form to watch on demand for free now.
Airfinity's cardio team outline the most impactful science presented in the field of lipid lowering therapies and novel antithrombotic drugs presented at the last two major cardiovascular conferences, ACC 2022 and ESOC 2022.
Discussion points include:
→ The strengths and limitations of late breaking trial data.
→ The development of novel candidates.
→ Results from the following trials: TRANSLATE-TIMI70, APOLLO, PACIFIC-AF, and ATTICUS
→ Insights into how these may affect treatment landscapes going forward.
Fill out the form to watch on demand for free now.
For press enquiries, please contact press@airfinity.com